US FDA First's RMAT Designation: Humacyte Got A 'Quick Response'
Executive Summary
Humacyte's bioengineered blood vessel, Humacyl, demonstrated long-term potency in Phase II studies; the product, which will regulated as a biologic, can now benefit from increased interactions with FDA under the the Regenerative Medicine Advanced Therapy program.
You may also be interested in...
Eight Pivotal Trial Read-Outs Expected In Q3
A number of pivotal studies are expected to report top-line data in the third quarter. Here, with the help of Informa Pharma's Biomedtracker, we take a look at eight of those likely to be major catalysts for their sponsors.
RMAT Designation, Gene Therapies Highlight 2017 CBER Transformation
CBER Director Peter Marks says the center implemented a lot in a short amount of time for the RMAT pathway.
JAMA Study Continues Wave Of Accelerated Approval Criticism Amid Expansion Of Pathway
Sponsors are increasingly using the accelerated approval pathway, but research continues to be critical about its aspects.